COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases.

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Myasthenia gravis (MG) is an autoimmune disease primarily mediated by acetylcholine receptor (AchR) antibodies, with contributions from cell-mediated immune response and complement activation.

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. Using anti-acetylcholine receptor ...

Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including ... given the heterogeneity of the disease, individual comorbidities, and the numerous ...

Nipocalimab is actually being developed across 3 segments of autoantibody-driven diseases. So we've talked about myasthenia gravis, which is a sort of directly autoantibody-driven rare disease.

The company is running three Phase II programs right now in primary biliary cholangitis, diabetes and myasthenia gravis. COUR will be facing some major Big Pharma peers in myasthenia; Argenx’s Vyvgart ...